Inhibition of HIV-1 envelope glycoprotein-mediated cell fusion by a DL-amino acid-containing fusion peptide: possible recognition of the fusion complex
- PMID: 15339935
- DOI: 10.1074/jbc.M403436200
Inhibition of HIV-1 envelope glycoprotein-mediated cell fusion by a DL-amino acid-containing fusion peptide: possible recognition of the fusion complex
Abstract
The N-terminal fusion peptide (FP) of human immunodeficiency virus-1 (HIV-1) is a potent inhibitor of cell-cell fusion, possibly because of its ability to recognize the corresponding segments inside the fusion complex within the membrane. Here we show that a fusion peptide in which the highly conserved Ile(4), Phe(8), Phe(11), and Ala(14) were replaced by their d-enantiomers (IFFA) is a potent inhibitor of cell-cell fusion. Fourier transform infrared spectroscopy confirmed that despite these drastic modifications, the peptide preserved most of its structure within the membrane. Fluorescence energy transfer studies demonstrated that the diastereomeric peptide interacted with the wild type FP, suggesting this segment as the target site for inhibition of membrane fusion. This is further supported by the similar localization of the wild type and IFFA FPs to microdomains in T cells and the preferred partitioning into ordered regions within sphingomyelin/phosphatidyl-choline/cholesterol giant vesicles. These studies provide insight into the mechanism of molecular recognition within the membrane milieu and may serve in designing novel HIV entry inhibitors.
Similar articles
-
Peptide and non-peptide HIV fusion inhibitors.Curr Pharm Des. 2002;8(8):563-80. doi: 10.2174/1381612024607180. Curr Pharm Des. 2002. PMID: 11945159 Review.
-
The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120.FEBS J. 2015 Dec;282(24):4643-57. doi: 10.1111/febs.13541. Epub 2015 Oct 22. FEBS J. 2015. PMID: 26432362 Free PMC article.
-
HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.Biochim Biophys Acta. 2012 Dec;1818(12):2950-7. doi: 10.1016/j.bbamem.2012.07.020. Epub 2012 Jul 31. Biochim Biophys Acta. 2012. PMID: 22867851
-
Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.Biochemistry. 2007 Apr 10;46(14):4360-9. doi: 10.1021/bi7001289. Epub 2007 Mar 20. Biochemistry. 2007. PMID: 17371053
-
[The current progress in the development of HIV-1 fusion inhibitors].Yao Xue Xue Bao. 2010 Feb;45(2):184-93. Yao Xue Xue Bao. 2010. PMID: 21351428 Review. Chinese.
Cited by
-
Insights into the mechanism of HIV-1 envelope induced membrane fusion as revealed by its inhibitory peptides.Eur Biophys J. 2011 Apr;40(4):349-57. doi: 10.1007/s00249-010-0666-z. Epub 2011 Jan 22. Eur Biophys J. 2011. PMID: 21258789 Review.
-
Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.Curr Top Med Chem. 2011 Dec;11(24):2959-84. doi: 10.2174/156802611798808497. Curr Top Med Chem. 2011. PMID: 22044229 Free PMC article. Review.
-
Candidate antibody-based therapeutics against HIV-1.BioDrugs. 2012 Jun 1;26(3):143-62. doi: 10.2165/11631400-000000000-00000. BioDrugs. 2012. PMID: 22462520 Free PMC article. Review.
-
A critical evaluation of the conformational requirements of fusogenic peptides in membranes.Eur Biophys J. 2007 Apr;36(4-5):405-13. doi: 10.1007/s00249-006-0106-2. Epub 2006 Nov 7. Eur Biophys J. 2007. PMID: 17089152
-
HIV-1 fusion peptide targets the TCR and inhibits antigen-specific T cell activation.J Clin Invest. 2005 Aug;115(8):2149-58. doi: 10.1172/JCI23956. Epub 2005 Jul 7. J Clin Invest. 2005. PMID: 16007266 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous